Acellular Tissue Engineered Vessel

Phase 3

HHumacyte, Inc.

Acellular Tissue Engineered Vessel is one of 3 therapeutic programs targeting Vascular. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

VascularNot yet recruiting

VascularPhase 3

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Vascular

#DrugCompanyPhaseTrials

Piqray

Novartis

Phase 2

1 2

Mekinist

Novartis

Phase 2

1 3

Acellular Tissue Engineered Vessel

HHumacyte, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Not yet recruiting

Vascular

NCT07762313

Q3 2030

ApprovedNot yet recruiting

Vascular

NCT07762794

Clinical

Trials by Indication[1]

Vascular2 trials

A Prospective, Multi-center, Open-label Study, to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury When Autologous Vein Graft is Not Feasible.

Not yet recruiting·HHumacyte, Inc.·Phase 3·NCT07762313·10 enrolled

A Phase 4 Observational Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting for Arterial Replacement or Reconstruction in Patients With Extremity Vascular Trauma

Not yet recruiting·HHumacyte, Inc.·Approved·NCT07762794·125 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Acellular Tissue Engineered Vessel. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Acellular Tissue Engineered Vessel. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Humacyte, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: HHumacyte, Inc.

Acellular Tissue Engineered Vessel

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2030

Trials by Indication[1]

Vascular2 trials

References

Drug Info

Quick Facts

Related News